Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease.


Journal

American journal of human genetics
ISSN: 1537-6605
Titre abrégé: Am J Hum Genet
Pays: United States
ID NLM: 0370475

Informations de publication

Date de publication:
06 06 2019
Historique:
received: 30 01 2019
accepted: 10 04 2019
pubmed: 21 5 2019
medline: 12 3 2020
entrez: 21 5 2019
Statut: ppublish

Résumé

Huntington disease (HD) is caused by a CAG repeat expansion in the huntingtin (HTT) gene. Although the length of this repeat is inversely correlated with age of onset (AOO), it does not fully explain the variability in AOO. We assessed the sequence downstream of the CAG repeat in HTT [reference: (CAG)n-CAA-CAG], since variants within this region have been previously described, but no study of AOO has been performed. These analyses identified a variant that results in complete loss of interrupting (LOI) adenine nucleotides in this region [(CAG)n-CAG-CAG]. Analysis of multiple HD pedigrees showed that this LOI variant is associated with dramatically earlier AOO (average of 25 years) despite the same polyglutamine length as in individuals with the interrupting penultimate CAA codon. This LOI allele is particularly frequent in persons with reduced penetrance alleles who manifest with HD and increases the likelihood of presenting clinically with HD with a CAG of 36-39 repeats. Further, we show that the LOI variant is associated with increased somatic repeat instability, highlighting this as a significant driver of this effect. These findings indicate that the number of uninterrupted CAG repeats, which is lengthened by the LOI, is the most significant contributor to AOO of HD and is more significant than polyglutamine length, which is not altered in these individuals. In addition, we identified another variant in this region, where the CAA-CAG sequence is duplicated, which was associated with later AOO. Identification of these cis-acting modifiers have potentially important implications for genetic counselling in HD-affected families.

Identifiants

pubmed: 31104771
pii: S0002-9297(19)30153-3
doi: 10.1016/j.ajhg.2019.04.007
pmc: PMC6556907
pii:
doi:

Substances chimiques

Codon 0
Peptides 0
polyglutamine 26700-71-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1116-1126

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

Copyright © 2019 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Références

Neurology. 2000 Jan 25;54(2):491-3
pubmed: 10668721
Genet Test. 2000;4(1):55-60
pubmed: 10794362
Clin Genet. 2000 Dec;58(6):469-72
pubmed: 11149616
J Med Genet. 2001 Apr;38(4):E12
pubmed: 11283208
Hum Mol Genet. 2001 Jul 1;10(14):1441-8
pubmed: 11448935
Am J Med Genet. 2001 Jul 8;105(5):399-403
pubmed: 11449389
Brain. 2001 Oct;124(Pt 10):1939-47
pubmed: 11571212
Hum Mol Genet. 2003 Dec 15;12(24):3359-67
pubmed: 14570710
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3498-503
pubmed: 14993615
Clin Genet. 2004 Apr;65(4):267-77
pubmed: 15025718
Hum Mol Genet. 2007 May 15;16(10):1133-42
pubmed: 17409200
Neurology. 2007 Nov 20;69(21):1970-5
pubmed: 17568014
Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):314-20
pubmed: 19455596
Hum Mol Genet. 2009 Aug 15;18(16):3039-47
pubmed: 19465745
Genome Med. 2009 Aug 21;1(8):80
pubmed: 19725930
Hum Mol Genet. 2012 May 15;21(10):2219-32
pubmed: 22328089
J Med Genet. 2013 Oct;50(10):696-703
pubmed: 23896435
Am J Med Genet B Neuropsychiatr Genet. 2013 Dec;162B(8):864-71
pubmed: 24038799
PLoS Genet. 2013 Oct;9(10):e1003930
pubmed: 24204323
Nat Neurosci. 2015 Jun;18(6):807-16
pubmed: 25938884
Mol Ther. 2015 Nov;23(11):1759-1771
pubmed: 26201449
Cell. 2015 Jul 30;162(3):516-26
pubmed: 26232222
Am J Hum Genet. 2016 Feb 4;98(2):287-98
pubmed: 26849111
Neurology. 2016 Jul 19;87(3):282-8
pubmed: 27335115
Nat Genet. 2016 Oct;48(10):1284-1287
pubmed: 27571263
Nat Neurosci. 2017 Apr;20(4):602-611
pubmed: 28263302
Lancet Neurol. 2017 Sep;16(9):701-711
pubmed: 28642124
Genome Res. 2017 Nov;27(11):1895-1903
pubmed: 28887402
Bioinformatics. 2019 May 27;:null
pubmed: 31134279
J Med Genet. 1995 May;32(5):399-400
pubmed: 7616551
Hum Mol Genet. 1995 Feb;4(2):189-95
pubmed: 7757066
Nat Genet. 1994 Apr;6(4):409-14
pubmed: 8054984
Hum Mol Genet. 1995 Oct;4(10):1911-8
pubmed: 8595415
Hum Mol Genet. 1997 Feb;6(2):301-9
pubmed: 9063751

Auteurs

Galen E B Wright (GEB)

Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC V5Z 4H4, Canada.

Jennifer A Collins (JA)

Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC V5Z 4H4, Canada.

Chris Kay (C)

Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC V5Z 4H4, Canada.

Cassandra McDonald (C)

Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC V5Z 4H4, Canada.

Egor Dolzhenko (E)

Illumina Inc, San Diego, CA 92121, USA.

Qingwen Xia (Q)

Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC V5Z 4H4, Canada.

Kristina Bečanović (K)

Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC V5Z 4H4, Canada; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm 171 77, Sweden.

Britt I Drögemöller (BI)

Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.

Alicia Semaka (A)

Department of Psychiatry, University of British Columbia, Vancouver, BC V6T 2A1, Canada.

Charlotte M Nguyen (CM)

The Hospital For Sick Children, The Centre for Applied Genomics, Genetics and Genome Biology, Toronto, ON M5G 0A4, Canada; University of Toronto, Department of Molecular Genetics, Toronto, ON M5G 0A4, Canada.

Brett Trost (B)

The Hospital For Sick Children, The Centre for Applied Genomics, Genetics and Genome Biology, Toronto, ON M5G 0A4, Canada.

Fiona Richards (F)

Department of Clinical Genetics, Children's Hospital at Westmead, Sydney, NSW 2145, Australia.

Emilia K Bijlsma (EK)

Department of Clinical Genetics, Leiden University Medical Center, Leiden 2333, the Netherlands.

Ferdinando Squitieri (F)

Huntington and Rare Diseases Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo 71013, Italy.

Colin J D Ross (CJD)

Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.

Stephen W Scherer (SW)

The Hospital For Sick Children, The Centre for Applied Genomics, Genetics and Genome Biology, Toronto, ON M5G 0A4, Canada; University of Toronto, Department of Molecular Genetics, Toronto, ON M5G 0A4, Canada; McLaughlin Centre, University of Toronto, Toronto, ON M5G 0A4, Canada.

Michael A Eberle (MA)

Illumina Inc, San Diego, CA 92121, USA.

Ryan K C Yuen (RKC)

The Hospital For Sick Children, The Centre for Applied Genomics, Genetics and Genome Biology, Toronto, ON M5G 0A4, Canada; University of Toronto, Department of Molecular Genetics, Toronto, ON M5G 0A4, Canada.

Michael R Hayden (MR)

Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC V5Z 4H4, Canada. Electronic address: mrh@cmmt.ubc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH